

## Evaluation and management of Mallory – Weiss syndrome

### **Abstract:**

Upper gastrointestinal bleeding is a symptom of Mallory-Weiss syndrome, which is caused by longitudinal mucosal lacerations (known as Mallory-Weiss tears) near the gastroesophageal junction or gastric cardia. Mallory-Weiss syndrome is rather prevalent, accounting for 3 to 10% of all upper gastrointestinal bleeding episodes. In mild circumstances, the disease may be asymptomatic. Hematemesis is the presenting symptom in 85 percent of patients. Blood is present in varying amounts, ranging from blood-streaked mucous to huge bright red haemorrhage. Other symptoms such as melena, dizziness, or syncope might occur as a result of heavy bleeding. The majority of the time, the bleeding is little and ends on its own. Endoscopy is frequently used to confirm the diagnosis of MWS. Although most patients may be treated with monitoring or conservative medicinal treatment, certain cases require endoscopic or surgical treatment. Despite the fact that MWS is a common cause of nonvariceal upper gastrointestinal bleeding (NVUGIB), little research has been done on it. In this article we'll be discussing MWS Etiology, epidemiology, evaluation and management

### **Introduction:**

Upper gastrointestinal bleeding is a symptom of Mallory-Weiss syndrome, which is caused by longitudinal mucosal lacerations (known as Mallory-Weiss tears) near the gastroesophageal junction or gastric cardia. Patients with continuous retching and vomiting after an alcoholic binge were the subject of the first description by Mallory and Weiss in 1929. However, any event that causes a rapid rise in intragastric pressure or gastric protrusion into the oesophagus, including prior transesophageal echocardiography, can cause Mallory-Weiss syndrome. Mallory-Weiss tears are responsible for 1 to 15% of all occurrences of upper gastrointestinal haemorrhage. Males are believed to have a 2-4:1 greater incidence than women, despite the fact that the age range is vast. Affected persons are often in their middle age (40s-50s). [1,2-4]

Endoscopy is frequently used to confirm the diagnosis of MWS. Near the GE junction, there is merely a break in the mucosa. The usual rip is 2-4 cm long, and the majority of patients only have one tear. On the smaller curvature, the rip is immediately beneath the GE connection. [5]

Mallory-Weiss syndrome is rather prevalent, accounting for 3 to 10% of all upper gastrointestinal bleeding episodes. The majority of the time, the bleeding is little and ends on its own. Active bleeding or symptoms of recent bleeding at endoscopy require prompt endoscopic hemostasis therapy. The most effective method for initial hemostasis and avoiding recurrent bleeding appears to be band ligation. In all circumstances, the use of proton pump inhibitors and antiemetics appears appropriate, despite the fact that there is no evidence of their effectiveness in the literature. [6]

Despite the fact that MWS is a common cause of nonvariceal upper gastrointestinal bleeding (NVUGIB), little research has been done on it. As we all know, endoscopic manipulation has progressed significantly, making early endoscopic intervention more accessible than it always was. Despite this, the rebleeding rate of MWS has remained between 5% and 10% for decades. There have been a number of grading systems developed to predict patient clinical outcomes as well as the requirement for hemostatic intervention. However, because peptic ulcer bleeding is the most prevalent cause of NVUGIB, the majority of them concentrated on it. [7-15]

### **Etiology:**

Heavy alcohol use is one of the most prominent predisposing variables, with roughly 50 percent to 70% of people diagnosed with Mallory-Weiss syndrome having a history of it. With Mallory-Weiss syndrome, the severity of upper GI bleeding is also known to be greater when portal hypertension and esophageal varices are present. [5] Mallory-Weiss tears with transesophageal echocardiography (MWa) may represent a different clinical condition from Mallory-Weiss tears without TEE (MWu). Cappell et al found that MWa patients had a considerably longer mean age, higher rates of concurrent anticoagulation, and higher mortality in a study of the literature that included 17 recognised instances of MWa and a reported series of 73 cases of MWu. [1,3] The link between Mallory-Weiss syndrome and a hiatal hernia (a protrusion of an organ,

generally the upper section of the stomach into the chest cavity through the esophageal aperture of the diaphragm) is still up for question. A hiatal hernia was detected in a significant proportion of Mallory-Weiss syndrome cases, but a case-control study at the Mayo Clinic in Florida reported no difference in the incidence of a hiatal hernia between Mallory-Weiss syndrome patients and the control group. [5]

The most common cause of retching and vomiting has traditionally been considered to be binge drinking. Despite this, a study discovered that MWS was linked to alcohol intake in only 17.9% of Chinese female patients in that research. Peptic ulcer, gastric cancer, and Dieulafoy disease with complications such as haemorrhage or obstruction were shown to predispose 12 female patients (42.9%) to vomiting. Furthermore, in men, underlying gastrointestinal illness was the second most common cause of vomiting (31.0 percent). These findings showed that underlying stomach illness, particularly in Chinese female MWS patients, is another key cause of vomiting. As a result, when a patient with bleeding MWS is admitted to the hospital, physicians should proceed with caution during the endoscopic examination in case the patient has underlying stomach illnesses. [7]

### **Epidemiology:**

In the United States, MWS is responsible for 1% to 15% of the causes of upper GI bleeding in adults and fewer than 5% in children. The peak incidence occurs between the ages of 40 and 60. For unknown causes, males are 2 to 4 times more likely than females to acquire Mallory-Weiss syndrome. Because hyperemesis is a common cause of Mallory-Weiss syndrome in young women, pregnancy testing should be explored. [5]

According to many research, MWS accounts for 3 percent to 15% of all NVUGIB cases. MWS is a relatively uncommon cause of NVUGIB, as seen by the incidence (6.1 percent). MWS, on the other hand, has a fatality rate comparable to peptic ulcer bleeding in high-risk individuals with bleeding. The majority of previous NVUGIB findings are focused on peptic ulcer bleeding. MWS-focused research is uncommon. The GBS and AIMS65 systems are intended to determine if a patient with acute NVUGIB will require a blood transfusion or endoscopic intervention. [7,16-22]

## **History, Physical Examination & Evaluation:**

In mild circumstances, the disease may be asymptomatic. Hematemesis is the presenting symptom in 85 percent of patients. Blood is present in varying amounts, ranging from blood-streaked mucous to huge bright red haemorrhage. Other symptoms such as melena, dizziness, or syncope might occur as a result of heavy bleeding. The presence of epigastric discomfort typically indicates the existence of a predisposing condition such as gastroesophageal reflux disease (GERD). [5] Melena, hematochezia, syncope, and stomach pain are less common presenting symptoms; excessive alcohol consumption has been documented in 40-75 percent of patients, and aspirin usage has been observed in up to 30 percent of patients. [1]

Mallory-Weiss syndrome has no distinct physical symptoms, and the symptoms are comparable to those of any other hemorrhagic illness or shock. Clinicians must look for symptoms of severe bleeding and shock during a physical examination, such as tachycardia, thready pulse, hypotension, dehydration, diminished skin turgor, and capillary filling time, and treat quickly if they are present. Melena may be detected during a rectal examination. [5]

Both the GBS system and the shocking index were successful in predicting the need for a transfusion. GBS is a more accurate system than the shocking index. However, because the GBS system is considerably more complex than the startling index, the shocking index may be a helpful signal for swiftly anticipating transfusion. GBS, on the other hand, seemed to have the best AUC when these scoring systems were used to predict the requirement for endoscopic intervention, followed by shock index. The AUC of the AIMS65 system seems to be the lowest. However, none of them were statistically significant. In a nutshell, the GBS and AIMS65 systems are ineffective in predicting the need for endoscopic intervention in MWS patients. GBS and AIMS65 scores may be high in certain individuals due to underlying gastrointestinal problems rather than the severity of MWS. As a result, the GBS system and AIMS65 may be ineffective in treating MWS caused by underlying gastrointestinal disorders. [7]

Laboratory tests used to assess the patient's clinical health include hematologic investigations, chemistries, and type and screen.

To measure the severity of the initial bleeding episode and to monitor patients, obtain haemoglobin and hematocrit tests. Platelet count, prothrombin time (PT), and activated partial thromboplastin time (aPTT) are also used to check for severe thrombocytopenia and coagulopathy, which can be serious complications. Coagulation tests are required in individuals taking anticoagulants or taking antibiotics with little or no oral intake. Because of the alcohol, the platelet count may be low. To guide intravenous fluid treatment, blood urea nitrogen (BUN), creatinine, and electrolyte levels are examined, as well as a blood type and antibody test for prospective blood transfusions. [1]

### **Treatment:**

Although most patients may be treated with monitoring or conservative medicinal treatment, certain cases require endoscopic or surgical treatment. For individuals with risk factors such as portal hypertension or coagulopathy, intensive treatment, including endoscopic hemostasis, has been suggested. In individuals with active bleeding MWT, an endoscopic examination is essential for diagnosis and therapy (e.g., arterial spurting and diffuse oozing). Stigmata on index endoscopy (e.g., non-bleeding visible vasculature and adhering clots) may not always require endoscopic therapy unless there has been a rebleeding episode or they are linked with coagulopathy. In such circumstances, endoscopic hemostasis is the preferred therapy. Injection therapy, contact heat treatment, argon plasma coagulation (APC), hemoclip implantation, and band ligation are the most frequent endoscopic therapies for actively bleeding MWT. [23]

There are two types of ESD procedures: traditional ESD and endoscopic submucosal tunnel dissection (ESTD) (Figure 1). (Figure1). 1). The standard ESD approach included four steps: (1) marking the lesion's border; (2) submucosal injection to raise the lesion; (3) mucosal incision around the lesion; and (4) submucosal dissection. During the dissection phase of ESTD, one or more submucosal tunnels were formed. The endoscopist determined the ESD treatment based on the size of the lesion. [24]

**Endoscopic injection therapy:** Endoscopic injection treatment uses a variety of drugs, the most common of which is epinephrine. Injection therapy is a simple, straightforward, and generally low-cost first-line treatment. When compared to supportive measures alone, epinephrine injection treatment improves outcomes

in terms of recurrent bleeding, hospital stay, and transfusion demand. Because epinephrine is absorbed into the systemic circulation, it can produce ventricular tachycardia when used for injectable treatment. In individuals with a history of coronary artery disease, injection treatment should be avoided. [23]

**Endoscopic electrocoagulation:** Electrocoagulation allows for simultaneous application of heat and pressure to a bleeding lesion. Coagulation is less efficient on a moist field, such as a bleeding site, since the heat is quickly dissipated by the liquid. For lesions on the lesser curvature of the cardia, proper placement of the device has proved difficult. Multipolar electrocoagulation considerably improved hemostasis, decreased surgery in patients with actively bleeding MWT, and had minor side effects. Because of the relatively thin esophageal wall and absence of serosa at the tear site, recurrent coagulation poses a risk of transmural damage and perforation. [23,25]

**Endoscopic hemoclip placement:** Endoscopic hemoclip implantation is a simple treatment for treating nonfibrotic tissue bleeding lesions like MWT and Dieulafoy ulcers. Hemoclip placement is tricky and perhaps more technically demanding because to the MWT bleeding position at the gastroesophageal (GE) junction. Controlled hemoclip alignment and simple access to the GE junction are made possible by a freshly invented rotatable mechanism on the delivery catheter. Because of the large amplitude contractions at this anatomic region, hemoclip detachment in the GE junction is common. Endoclip implantation can repair both tearing edges to seal the perforated lesion in the case of a deeper tear extension, such as with Boerhaave syndrome. [23]

**Endoscopic band ligation:** The fundamental benefit of endoscopic band ligation (EBL) over other hemostatic techniques is its technological simplicity. Under direct pressure from a transparent ligation cap, the lesion is well visible tangentially in EBL. EBL is particularly beneficial for bleeding lesions in nonfibrotic tissue, when esophageal perforation is a real possibility. By immobilising the bleeding site and preventing movement from peristalsis and belching, the clear cover makes EBL easier to operate. The deeper part of the visible vessel is ligated, ensuring definitive hemostasis and strong insertion of the ligated band. Large MWT can also be treated with just one band ligation. [23] There was no difference in the effectiveness or safety of band ligation vs epinephrine injection in a short,

prospective, randomised investigation of 34 individuals with actively bleeding lesions. Thermal treatment is not advised for bleeding Mallory-Weiss tears associated with portal hypertension and gastric varices, thus band ligation should be used instead. [1,26]

In a patient with a severe upper gastro-intestinal bleeding for which a definitive preoperative diagnosis is not achievable, the surgeon must consider all options. If there is no duodenal or gastric lesion, a broad gastrotomy is required with the abdomen open. At this point, a blind gastrectomy is not recommended since bleeding from the oesophagus or cardia will go unnoticed and untreated. The cause of the bleeding will be determined when the anterior wall of the stomach has been incised for a distance of five to seven inches and judicious application of packs. The proximal stomach Mallory-Weiss lacerations will quickly show up and may be repaired with a running catgut suture. If the blood comes from the oesophagus, a higher level of exposure is necessary. [27]

In a study by (C Sugawa, et al.) Mallory-Weiss syndrome was discovered to be the source of upper gastrointestinal bleeding in 224 of 2,175 (10.3 percent) patients investigated, owing to the increased early use of endoscopy. Because Mallory-Weiss syndrome is a self-limiting disease in more than 90% of patients, conservative treatment, which includes multiple transfusions, electrocoagulation, and compression with a Sengstaken-Blakemore tube, are the preferred treatment, especially in medically debilitated patients. Cirrhotic patients are very difficult to treat and, regardless of therapy, have a dismal prognosis. In a limited subset of individuals, stomach prolapse into the oesophagus may be an etiologic cause. [28]

### **Conclusion:**

Mallory-Weiss syndrome is no doubt one of concerning conditions that exist. Mallory-Weiss syndrome is rather prevalent, accounting for 3 to 10% of all upper gastrointestinal bleeding episodes. Even though in many cases may be asymptomatic Hematemesis is the presenting symptom in 85 percent of patients. At this point endoscopy seems to be treatment of choice for many patients and is preferred over the traditional surgical methods due to decreased recovery time, and less complications.

## References:

1. Louis Michel Wong Kee Song, Praveen K Roy, et al. Mallory-Weiss Tear Overview of Mallory-Weiss Syndrome. Updated: Oct 02, 2019. Medscape <https://emedicine.medscape.com/article/187134-overview>
2. Mallory GK, Weiss SW. Hemorrhages from lacerations of the cardiac orifice of the stomach due to vomiting. *Am J Med Sci.* 1929. 178:506-12.
3. Cappell MS, Dass K, Manickam P. Characterization of the syndrome of UGI bleeding from a Mallory-Weiss tear associated with transesophageal echocardiography. *Dig Dis Sci.* 2014 Oct. 59(10):2381-9.
4. Sugawa C, Benishek D, Walt AJ. Mallory-Weiss syndrome. A study of 224 patients. *Am J Surg.* 1983 Jan. 145(1):30-3.
5. Rawla P, Devasahayam J. Mallory Weiss Syndrome. [Updated 2021 Aug 9]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK538190/>
6. Leclaire S, Antonietti M, Ducrotté P. Syndrome de Mallory-Weiss : diagnostic et traitement [Mallory-Weiss syndrome: diagnosis and treatment]. *Presse Med.* 2010 Jun;39(6):640-4. French. doi: 10.1016/j.lpm.2009.09.019. PMID: 19931377.
7. He L, Li ZB, Zhu HD, Wu XL, Tian DA, Li PY. The prediction value of scoring systems in Mallory-Weiss syndrome patients. *Medicine (Baltimore).* 2019 May;98(22):e15751. doi: 10.1097/MD.00000000000015751. PMID: 31145291; PMCID: PMC6709145.
8. Bharucha AE, Gostout CJ, Balm RK. Clinical and endoscopic risk factors in the Mallory-Weiss syndrome. *Am J Gastroenterol* 1997;92:805-8.
9. Yin A, Li Y, Jiang Y, et al. Mallory-Weiss syndrome: clinical and endoscopic characteristics. *Eur J Intern Med* 2012;23:e92-6.

10. Chung IK, Kim EJ, Hwang KY, et al. Evaluation of endoscopic hemostasis in upper gastrointestinal bleeding related to Mallory-Weiss syndrome. *Endoscopy* 2002;34:474–9.
11. Cho YS, Chae HS, Kim HK, et al. Endoscopic band ligation and endoscopic hemoclip placement for patients with Mallory-Weiss syndrome and active bleeding. *World J Gastroenterol* 2008;14:2080–4.
12. Park CH, Min SW, Sohn YH, et al. A prospective, randomized trial of endoscopic band ligation vs. epinephrine injection for actively bleeding Mallory-Weiss syndrome. *Gastrointest Endosc* 2004;60:22–7.
13. Cybułka B. Mallory-Weiss syndrome based on own experience – diagnostics and modern principles of management. *Pol Przegl Chir* 2016;88:77–86.
14. Rockall TA, Logan RF, Devlin HB, et al. Risk assessment after acute upper gastrointestinal haemorrhage. *Gut* 1996;38:316–21.
15. Blatchford O, Murray WR, Blatchford M. A risk score to predict need for treatment for upper-gastrointestinal haemorrhage. *Lancet* 2000;356:1318–21.
16. Kim JW, Kim HS, Byun JW, et al. Predictive factors of recurrent bleeding in Mallory-Weiss syndrome. *Korean J Gastroenterol* 2005;46:447–54.
17. Katz PO, Salas L. Less frequent causes of upper gastrointestinal bleeding. *Gastroenterol Clin North Am* 1993;22:875–89.
18. Crooks CJ, West J, Card TR. Upper gastrointestinal haemorrhage and deprivation: a nationwide cohort study of health inequality in hospital admissions. *Gut* 2012;61:514–20.
19. Kim JJ, Sheibani S, Park S, et al. Causes of bleeding and outcomes in patients hospitalized with upper gastrointestinal bleeding. *J Clin Gastroenterol* 2014;48:113–8.
20. Ljubicic N, Budimir I, Pavic T, et al. Mortality in high-risk patients with bleeding Mallory-Weiss syndrome is similar to that of peptic ulcer bleeding. Results of a prospective database study. *Scand J Gastroenterol* 2014;49:458–64.
21. Bai Y, Li ZS. Guidelines for the diagnosis and treatment of acute non-variceal upper gastrointestinal bleeding (2015, Nanchang, China). *J Dig Dis* 2016;17:79–87.

22. Lee S, Ahn JY, Jung HY, et al. Effective endoscopic treatment of Mallory-Weiss syndrome using Glasgow-Blatchford score and Forrest classification. *J Dig Dis* 2016;17:676–84.
23. Kim HS. Endoscopic management of mallory-weiss tearing. *Clin Endosc*. 2015 Mar;48(2):102-5. doi: 10.5946/ce.2015.48.2.102. Epub 2015 Mar 27. PMID: 25844336; PMCID: PMC4381135.
24. Chen W, Zhu XN, Wang J, Zhu LL, Gan T, Yang JL. Risk factors for Mallory-Weiss Tear during endoscopic submucosal dissection of superficial esophageal neoplasms. *World J Gastroenterol*. 2019 Sep 14;25(34):5174-5184. doi: 10.3748/wjg.v25.i34.5174. PMID: 31558865; PMCID: PMC6747285.
25. Multipolar electrocoagulation in the treatment of active upper gastrointestinal tract hemorrhage. A prospective controlled trial. *Laine LN Engl J Med*. 1987 Jun 25; 316(26):1613-7.
26. A prospective, randomized trial of endoscopic band ligation vs. epinephrine injection for actively bleeding Mallory-Weiss syndrome. *Gastrointest Endosc*. 2004; 60(1):22-7 (ISSN: 0016-5107) Park CH; Min SW; Sohn YH; Lee WS; Joo YE; Kim HS; Choi SK; Rew JS; Kim SJ
27. ZEIFER HD. Mallory-Weiss syndrome. *Ann Surg*. 1961 Dec;154(6):956-60. PMID: 14010021; PMCID: PMC1465928.
28. Sugawa C, Benishek D, Walt AJ. Mallory-Weiss syndrome. A study of 224 patients. *Am J Surg*. 1983 Jan;145(1):30-3. doi: 10.1016/0002-9610(83)90162-9. PMID: 6600377.